<DOC>
	<DOCNO>NCT02608359</DOCNO>
	<brief_summary>The purpose study evaluate safety abiraterone acetate Indian participant metastatic , castration-resistant prostate cancer prescribe abiraterone acetate per locally approve prescribing information .</brief_summary>
	<brief_title>A Post-marketing Surveillance Assess Safety Abiraterone Acetate ( Zytiga ) Indian Participants With Metastatic , Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>This prospective ( participant identify follow forward time outcome study ) , multicenter ( one hospital medical school team work medical research study ) , post-marketing surveillance ( [ PMS ] , surveillance drug , device , appliance , etc. , efficacy adverse effect , release general sale ) study . The study consist Screening Enrolment Visit ( Day 1 ) Follow-up Period ( 12 month ) . For participant , follow-up visit conduct per routine clinical practice month 3 , 6 9 . The End-of-Study ( EOS ) Visit conduct completion 12-months abiraterone acetate ( Zytiga ) telephonic follow-up conduct 30 day EOS Visit . The total duration study 13 month . Participants receive abiraterone acetate per locally approve prescribe information enrol PMS . The use abiraterone acetate follow dose frequency stipulate locally approve prescribing information . Participants monitor treatment abiraterone acetate 30 day post treatment collection adverse event . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Participants establish diagnosis metastatic castrationresistant prostate carcinoma Being newly initiate Zytiga treatment ( abiraterone acetate tablet 250 mg ) base independent clinical judgment treat physician per locally approve prescribe information Willing provide write informed consent indicate understand purpose willing participate postmarketing surveillance ( PMS ) Participants eligible receive Zytiga per locally approve prescribe information Participants participate plan participate interventional drug trial course PMS</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Post-Marketing Surveillance</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>Zytiga</keyword>
</DOC>